Centralized price bidding

Drug developer Shanghai Junshi Biosciences said on Sunday its board has approved a plan to buy back some of its A-shares.

FAST NEWS: Junshi Biosciences announces A-Share buyback

The latest: Drug developer Shanghai Junshi Biosciences Co. Ltd. (1877.HK; 688180.SH) said on Sunday its board has approved a plan to buy back some of its A-shares for up to 58 yuan per…
1877.HK 688180.SHG

Recent Articles

RELATED ARTICLES

  1. Everest Medicines eyes cash break even
    Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
    1952.HK
  2. Cash-hungry Mabwell seeks financial tonic from Hong Kong investors
    688062.SHG
  3. Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
    1952.HK
  4. As Covid drug cash dwindles, Vigonvita targets new remedies
  5. Jinko sees sunnier skies in Germany with new fundraising plan
    JKS.US 688223.SHG
  6. Cancer drug maker Genfleet joins Hong Kong IPO influx
  7. BeiGene heads for profit milestone after hemorrhaging cash
    6160.HK ONC.US 688235.SHG
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva